Optimization of Important Early ADME(T) Parameters of NADPH Oxidase-4 Inhibitor Molecules

被引:3
作者
Borbely, Gabor [1 ,2 ]
Huszar, Monika [1 ]
Varga, Attila [1 ,2 ]
Futosi, Krisztina [4 ]
Mocsai, Attila [4 ]
Orfi, Laszlo [2 ,3 ,5 ]
Idei, Miklos [1 ]
Mandl, Jozsef [6 ]
Keri, Gyoergy [1 ,2 ,3 ]
Vantus, Tibor [1 ]
机构
[1] Semmelweis Univ, Dept Med Chem, Pathobiochem Res Grp, Hungarian Acad Sci, Budapest, Hungary
[2] Semmelweis Univ, Rat Drug Design Lab CRC, Budapest, Hungary
[3] Vichem Chem Res Ltd, Budapest, Hungary
[4] Semmelweis Univ, Fac Med, Dept Physiol, Budapest, Hungary
[5] Semmelweis Univ, Dept Pharmaceut Chem, Budapest, Hungary
[6] Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, Budapest, Hungary
关键词
ADME(T); characterization; compounds; disease; inhibitor; NADPH oxidase 4; relationship; ARTIFICIAL MEMBRANE; LIPOPHILICITY; PERMEABILITY;
D O I
10.2174/157340612800493674
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Through their reactive oxygen species (ROS) producing function, NADPH oxidase (NOX) enzymes have been linked to several oxidative stress related diseases. In our recently published paper [1] we have already shown the NOX4 inhibitory effect of diverse, molecule sub-libraries and their biological importance. We also presented our work connected to potential anti-tumour molecules and the relationship between their biological activity and physico-chemical properties [2]. As an extension of these studies further physico-chemical and biological investigation has been carried out on a molecule group included NOX4 inhibitory chromanone compounds. Here we describe the optimization of early ADME(T) parameters determining lipophilicity, phospholipophilicity and permeability linked to structure-activity relationship. We prove that optimal lipo-and phospholipophilicty can be also determined in case of NOX4 inhibitors and a comparison will be made between the chemically similar isochromanone and chromanone molecular libraries. It will be also shown how to predict the effect of different substituents on permeability, lipo- and phospholipophilicity and also the biological differences between anti-tumour molecules and NOX4 inhibitors according to their penetration ability.
引用
收藏
页码:174 / 181
页数:8
相关论文
共 22 条
[1]  
[Anonymous], [No title captured], Patent No. [5,843,990, 5843990]
[2]   Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA pKaflux method [J].
Avdeef, A ;
Artursson, P ;
Neuhoff, S ;
Lazorova, L ;
Gråsjö, J ;
Tavelin, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 24 (04) :333-349
[3]   The neutrophil NADPH oxidase [J].
Babior, BM ;
Lambeth, JD ;
Nauseef, W .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2002, 397 (02) :342-344
[4]   Mitochondria, oxidants, and aging [J].
Balaban, RS ;
Nemoto, S ;
Finkel, T .
CELL, 2005, 120 (04) :483-495
[5]   The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology [J].
Bedard, Karen ;
Krause, Karl-Heinz .
PHYSIOLOGICAL REVIEWS, 2007, 87 (01) :245-313
[6]   Small-Molecule Inhibitors of NADPH Oxidase 4 [J].
Borbely, Gabor ;
Szabadkai, Istvan ;
Horvath, Zoltan ;
Marko, Peter ;
Varga, Zoltan ;
Breza, Nora ;
Baska, Ferenc ;
Vantus, Tibor ;
Huszar, Monika ;
Geiszt, Miklos ;
Hunyady, Laszlo ;
Buday, Laszlo ;
Orfi, Laszlo ;
Keri, Gyoergy .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (18) :6758-6762
[7]   A novel design of artificial membrane for improving the PAMPA model [J].
Chen, Xiaoxi ;
Murawski, Anthony ;
Patel, Karishma ;
Crespi, Charles L. ;
Balimane, Praveen V. .
PHARMACEUTICAL RESEARCH, 2008, 25 (07) :1511-1520
[8]   Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data [J].
Dreassi, Elena ;
Zizzari, Alessandra Tania ;
Falchi, Federico ;
Schenone, Silvia ;
Santucci, Annalisa ;
Maga, Giovanni ;
Botta, Maurizio .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (09) :3712-3717
[9]   Endothelial dysfunction [J].
Endemann, DH ;
Schiffrin, EL .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :1983-1992
[10]   Physiological roles of xanthine oxidoreductase [J].
Harrison, R .
DRUG METABOLISM REVIEWS, 2004, 36 (02) :363-375